Elzasonan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Elzasonan
Elzasonan structure.svg
Systematic (IUPAC) name
4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 220322-05-4 YesY
ATC code none
PubChem CID 19544192
CID 6914152
ChemSpider 5290108
UNII 933PJL964R YesY
Chemical data
Formula C22H23Cl2N3OS
Molar mass 448.4085 g/mol
  (verify)

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also[edit]

References[edit]